Johnson & Johnson (J&J) has announced US FDA approval for Tecvayli (teclistamab-cqyv) plus Darzalex Faspro (daratumumab and hyaluronidase-fihj) to treat adults with relapsed or refractory multiple ...

Stage 1 multiple myeloma features low beta-2 microglobulin, high albumin, and no organ damage, often detected incidentally. Diagnosis involves blood, urine, imaging tests, and bone marrow biopsy to ...

The approval was supported by data from the ongoing Phase III MajesTEC-3 study.

A “significant number of patients” could see a cure for multiple myeloma within the next two decades, one expert told ...

Relapsed and refractory multiple myeloma can be difficult to manage, especially as patients progress through multiple lines of therapy and treatment options may become more limited. 1 Since the ...

Clinical trial led by UAB researcher supports approval of new, potentially curative treatment for multiple myeloma ...

Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced that the U.S. Food and Drug Administration (FDA) approved TECVAYLI® (teclistamab-cqyv) plus DARZALEX ...

During a live event, Marc J. Braunstein, MD, PhD, and participants discussed maintenance lenalidomide and daratumumab as well as the clinical potential of MRD in multiple myeloma.

Chemotherapy is a treatment that uses strong medicines to kill cancer cells or slow their growth. It is a type of systemic therapy, which means it travels through the bloodstream to reach and attack ...

Natco Pharma launched a cheaper generic version of the cancer drug ‘Pomalyst’ in the U.S. to treat multiple myeloma, making ...

Bonnie was exhausted. It was late 2001, and she’d been working a high-pressure job – barely getting any sleep. “I’d wake up tired, I’d go to bed tired,” she says. She didn’t think much of it, but she ...

ASH Annual Meeting and Exposition leaves the oncology community buzzing over a series of late-breaking presentations that experts are calling 'unprecedented.' Major pharmaceutical developers such as ...